[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"axial-spondyloarthritis-axspa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:axial-spondyloarthritis-axspa":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,76,104,134,164,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100652563","the-effect-of-postural-bofeedback-on-dsease-actvty-and-pan-n-indvduals-wth-axal-spondyloarthrts-100652563",false,"NCT07776652","Postural Biofeedback and Exercise in Axial Spondyloarthritis","The Effect of Postural Biofeedback on Disease Activity and Pain in Individuals With Axial Spondyloarthritis","Inclusion Criteria:\n\n* Be between 18 and 65 years of age.\n* Have a diagnosis of ankylosing spondylitis or axial spondyloarthritis according to the modified New York or ASAS classification criteria.\n* Have had stable medical treatment with no changes in medication during the previous 3 months.\n* Have axial\u002Fspinal pain intensity of at least 4 out of 10 on the Numeric Pain Rating Scale during the previous week.\n* Be able to walk independently.\n* Voluntarily agree to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* History of spinal surgery within the previous 6 months.\n* Any change in medical treatment, including biological agents or analgesic treatment, within the previous 3 months.\n* Presence of fibromyalgia or another secondary chronic pain syndrome that may substantially affect pain perception.\n* Serious cardiopulmonary, neurological, or orthopedic conditions that prevent participation in exercise.\n* Pregnancy.\n* Dermatological or allergic skin reactions or other skin conditions that prevent the use of the wearable device.\n* Regular participation in a structured exercise or rehabilitation program supervised by a physiotherapist for axial spondyloarthritis within the previous 3 months.","ALL","18 Years","65 Years",{"count":20,"type":21},38,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether adding a wearable postural biofeedback device to a standard exercise program affects disease activity, pain, and functional parameters in individuals with axial spondyloarthritis. The main questions it aims to answer are:\n\nDoes adding postural biofeedback to a standard exercise program improve disease activity? Does adding postural biofeedback to a standard exercise program reduce pain? Does adding postural biofeedback improve functional parameters, including spinal mobility, quality of life, posture, and functional exercise capacity?\n\nResearchers will compare a standard exercise program with the same exercise program combined with a wearable postural biofeedback device to determine whether the addition of postural biofeedback provides greater benefits.\n\nParticipants will:\n\nParticipate in a physiotherapist-supervised standard exercise program twice a week for 8 weeks Use the wearable postural biofeedback device three days per week for at least 3 hours per day during prolonged static posture activities if assigned to the intervention group Complete assessments before and after the 8-week intervention, including measures of disease activity, pain, physical function, spinal mobility, quality of life, posture, and functional exercise capacity",[27,28],"Axial Spondyloarthritis (AxSpA)","Ankylosing Spondylitis (AS)",[30,31,32,33,34,35],"Axial Spondyloarthritis","Biofeedback","Postural Biofeedback","Exercise Therapy","Posture","Disease Activity","NOT_YET_RECRUITING","2026-08-19",{"date":39,"type":40},"2026-08-21","ACTUAL",{"date":42,"type":21},"2026-10-01",{"date":44,"type":21},"2027-06-30",{"name":46,"class":47},"Istanbul University - Cerrahpasa","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100652239","phase-4-a-pragmatic-trial-of-interleukin-17-inhibition-versus-janus-kinase-inhibition-after-tumor-necrosis-factor-alpha-inhibitor-failure-in-axial-spondyloarthritis-100652239","NCT07770646","A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis","A Pragmatic Randomized Pilot Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis","Inclusion Criteria:\n\n* fulfill ASAS classification criteria for axSpA and\u002For modified New York classification criteria for AS\n* Active axSpA (ASDAS ≥ 2.1 and\u002For BASDAI ≥ 4)\n* Failure of or intolerance to ≥1 TNF\n* Participants of reproductive potential must agree to use any form of effective contraception during the study period, in accordance with standard clinical practice and FDA labeling for the assigned study medication\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Previously received an IL-17i or JAKi\n* Active infection requiring antimicrobials\n* Contraindications to either treatment arm:\n\n  * Inflammatory bowel disease (IBD)- Crohn's disease or Ulcerative Colitis\n  * Active cancer or cancer remission within the past 3 years (apart from non-melanoma skin cancer (NMSC) and cervical intraepithelial neoplasia (CIN)\n  * History of stroke, heart attack, or blood clots (venous or arterial)\n  * Cirrhosis\n  * End-stage renal disease (GFR \\\u003C15) or dialysis\n  * Human Immunodeficiency Virus (HIV) positive\n  * Pregnant or lactating\n* Concomitant use of other biologic or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) therapy",{"count":57,"type":21},40,[59],"PHASE4","The purpose of this study is to determine the feasibility of conducting a pragmatic trial of IL-17i versus JAKi in adults with axial spondyloarthritis (axSpA) who have failed at least one tumor necrosis factor-alpha inhibitor (TNFi), to estimate the effectiveness of IL-17i versus JAKi at 16 weeks and to determine additional effectiveness measures, safety, and treatment persistence of IL-17i versus JAKi",[27],[63,64,65,66],"comparative effectiveness","axial spondyloarthritis","secukinumab","upadacitinib","2026-08-12",{"date":69,"type":40},"2026-08-18",{"date":71,"type":21},"2026-09-14",{"date":73,"type":21},"2029-09-15",{"name":75,"class":47},"The University of Texas Health Science Center, Houston",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100596610","phase-1-east-1-erap-inhibition-in-axial-spondyloarthritis-trial---1-100596610","NCT07047703","EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)","A Multi-part, Phase I\u002FII Study to Evaluate the Safety and Tolerability of GRWD0715 in Healthy Human Volunteers and Participants With Axial Spondyloarthritis","EAST-1","Inclusion Criteria:\n\nHealthy Volunteers\n\n* Healthy male and female subjects aged 18-55 years inclusive, at the Screening visit\n* Participant must provide written informed consent to participate in the study\n* Participant must be able and willing to comply with the requirements of the protocol (including dietary restrictions and exclusion of grapefruit juice)\n* Male participants (and their female partners) \u002F female participants must be willing to adhere to contraception requirements as detailed in the protocol\n* Non-smokers or ex-smokers who have not smoked within the previous 6 months, as determined at the Screening visit\n* Participant with a Body Mass Index (BMI) of 19-30. Body Mass Index = Body weight (kg) \u002F \\[Height (m)\\]2\n\nAxSpA Participants\n\n* Male or female, 18-65 years of age\n* Participants diagnosed with Axial Spondyloarthritis, also fulfilling ASAS classification criteria including:\n\n  1. HLA-B27 +ve (local testing)\n  2. Objective evidence of inflammation at screening, specifically active sacroiliac joint inflammation on MRI fulfilling the ASAS MRI criteria (MRI+), assessed by the Principal Investigator or appropriately trained delegate, and\u002For elevated C-reactive protein (CRP+) ≥5.0mg\u002FL.\n* Symptom duration of ≥3 months\n* Age at onset of active disease of \\\u003C40 years\n* A score of ≥ 2.1 on the Ankylosing Spondylitis Disease Activity Score (ASDAS) on current treatment.\n* At least one of the following:\n\n  1. Current treatment with a NSAID, at a sufficient dose and following an appropriate dosing duration per local clinical guidelines, with inadequate clinical response OR\n  2. Intolerance to ≥1 NSAID or contraindication(s) to NSAIDs\n* Participants may have received 1 prior\u002F(Australia only) 2 prior b\u002Fts DMARD and discontinued due to intolerance or inadequate efficacy.\n* Participants who have received 1\u002F(Australia only) 2 prior treatments are required to undergo a washout at minimum:\n\n  1. Biologic DMARDs 4 weeks or 5 half-lives prior to Day 1, whichever is longer.\n  2. JAK inhibitor DMARDs 2 weeks prior to Day 1\n\nExclusion Criteria:\n\nHealthy Volunteers\n\n* History or presence of any clinically significant findings in medical history, physical examination, vital signs and\u002For laboratory tests that, in the opinion of the Investigator, would preclude inclusion in the study\n* Participation in a New Chemical Entity clinical study within the previous 124 days or a marketed drug clinical study within the previous 93 days\n* Known infection or lifestyle risk factors for human immunodeficiency virus (HIV) and\u002For hepatitis B or C infection, as determined at the Screening visit\n\nAxSpA Participants\n\n* Participants who have received \\>1\u002F(Australia only) \\>2 biologic or JAK inhibitor DMARD or are receiving any other disease-modifying antirheumatic drugs (other than those allowed), thalidomide (including previous use) and other prohibited concomitant medications.\n* Inadequate Haematologic function, defined as:\n\n  1. Haemoglobin \\\u003C10 g\u002FdL.\n  2. Absolute white blood cell count \\\u003C3.0 x 109 \u002FL (\\\u003C3000 mm3)\n  3. Absolute neutrophil count \\\u003C1.2 x 109 \u002FL (\\\u003C1200 mm3)\n  4. Absolute lymphocyte count \\\u003C1.0 x 109 \u002FL (\\\u003C1000 mm3)\n  5. Platelet count \\\u003C100 x 109 \u002FL (\\\u003C100.000 mm3)\n* Inadequate liver function, defined as; total bilirubin, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) more than 1.5 times the upper limit of normal at screening visit. For subjects with Gilberts syndrome, upper limit of normal for total bilirubin will be 2.9mg\u002Fdl\n* History of any other autoimmune rheumatic disease (e.g., psoriatic arthropathy, systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymositis) or known diagnosis of fibromyalgia\n* Participants with a previous history of or currently stable psoriasis are eligible\n* Active or symptomatic inflammatory bowel disease (IBD). Participants with a history of IBD are allowed to participate\n* Presence of active anterior uveitis\n\nPlease note the following Country-Specific Inclusion Criteria, for study participants in Australia:\n\n\\- Participants with a score of ≥ 2.1 (High Disease Activity) on the Ankylosing Spondylitis Disease Activity Score (ASDAS) on current treatment.\n\nFor study participants in Part B only:\n\n* Objective evidence of inflammation may not be required for some participants with low to moderate disease activity.\n* Participants with an ASDAS score between ≥1.3 and \\\u003C 2.1 (Low to Moderate Disease Activity) will require Sponsor approval prior to screening for the study, as they may not require an MRI to provide objective evidence of inflammation if on current treatment. For participants with low to moderate disease activity, MRI should only be performed if required to confirm ASAS classification.\n\nFor axSpA participants in Part B, MRI assessment of the SI joints is only required for participant eligibility criteria evaluation to assess objective inflammation in case CRP measurement at baseline is negative and the objective evidence of inflammation is required.",{"count":85,"type":21},141,[87,88],"PHASE1","PHASE2","GRWD0715 is an orally administered, selective inhibitor of the Endoplasmic Reticulum Aminopeptidase 1 \\[ERAP1\\] enzyme being explored as a potential new treatment for axial spondyloarthritis (axSpA), a long term condition caused by inflammation predominantly affecting the sacroiliac joints (SIJs) and spine.",[27],[30,92],"AxSpA","RECRUITING","2026-07-22",{"date":96,"type":40},"2026-07-23",{"date":98,"type":40},"2025-07-28",{"date":100,"type":21},"2028-09-30",{"name":102,"class":47},"Grey Wolf Therapeutics",16,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":114,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":48},"100648650","multicenter-validation-of-the-2025-classification-criteria-for-axial-spondyloarthritis-100648650","NCT07724847","Multicenter Validation of the 2025 Classification Criteria for Axial Spondyloarthritis","MVAS2025","Inclusion Criteria:\n\n* 1\\. Presence of current chronic back pain with duration ≥3 months and without a definitive diagnosis 2. Age at onset of back pain ≤45 years 3. Presentation to a rheumatologist for evaluation of suspected axial spondyloarthritis or related conditions, without a confirmed diagnosis of axSpA or other rheumatic diseases 4. Willingness to complete comprehensive diagnostic assessments including clinical history, physical examination, CRP testing, HLA-B27 testing, pelvic X-ray, and sacroiliac joint MRI (recent imaging may be acceptable if completed within appropriate timeframe) 5. Voluntary participation with provision of signed electronic informed consent\n\nExclusion Criteria:\n\n* 1\\. Inability to communicate due to cognitive impairment, visual impairment, or other factors affecting self-assessment 2. Confirmed diagnosis of axial spondyloarthritis (axSpA), ankylosing spondylitis (AS), or other established rheumatic diseases (e.g., rheumatoid arthritis, psoriatic arthritis) 3. Back pain duration \\\u003C3 months or age at onset \\>45 years 4. Refusal or inability to complete full diagnostic evaluation due to medical contraindications (e.g., metallic implants preventing MRI, severe hepatic or renal dysfunction precluding laboratory testing) 5. Presence of clearly identified non-SpA causes of chronic back pain with established diagnosis, including lumbar disc herniation, spinal stenosis, spinal tumors, infectious spondylitis, or osteoporotic fractures 6. Failure to provide informed consent, inability to cooperate with study follow-up, or inability to provide complete data","45 Years",{"count":113,"type":21},247,"1 Month","OBSERVATIONAL","This study aims to validate the 2025 ASAS-SPARTAN revised classification criteria for axial spondyloarthritis (axSpA) in the Chinese population through a multicenter, prospective, cross-sectional observational study.\n\nAxial spondyloarthritis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing back pain and stiffness. Early and accurate diagnosis is essential for timely treatment and improved patient outcomes. The 2025 ASAS-SPARTAN revised classification criteria were recently developed by the Assessment of SpondyloArthritis International Society (ASAS) and the SpondyloArthritis Research and Treatment Network (SPARTAN) to improve diagnostic accuracy and reduce over-diagnosis, with preset targets of sensitivity ≥75% and specificity ≥90%. However, the original validation study included only 71 Chinese patients out of 1,015 total participants, and racial differences in susceptibility genes, living environments, and socioeconomic-cultural backgrounds may affect the criteria's performance in Chinese patients.\n\nThis study will enroll patients with chronic back pain (CBP) lasting ≥3 months and onset age ≤45 years from multiple hospitals in China. All participants will undergo comprehensive diagnostic assessments including clinical history, physical examination, CRP testing, HLA-B27 testing, pelvic X-ray, and sacroiliac joint MRI. The 2025 ASAS-SPARTAN criteria will be applied to evaluate diagnostic performance, and results will be compared with the 2009 ASAS classification criteria and clinicians' gold-standard diagnoses.\n\nThe primary objective is to validate the sensitivity, specificity, and internal scoring rationality of the 2025 ASAS-SPARTAN criteria in Chinese axSpA patients. The secondary objective is to assess the concordance between the 2025 and 2009 ASAS criteria and analyze reasons for any discrepancies.\n\nThe findings will provide evidence for Chinese clinicians to select appropriate classification tools, reduce over-diagnosis of axSpA, and alleviate the burden on the healthcare system.",[27,118,119],"Spondyloarthritis (SpA)","Chronic Back Pain",[121,122,123,124],"Classification Criteria","Validation","Diagnostic Accuracy","ASAS-SPARTAN","2026-07-21",{"date":127,"type":40},"2026-07-24",{"date":129,"type":40},"2026-04-10",{"date":131,"type":21},"2027-04-10",{"name":133,"class":47},"Chinese PLA General Hospital",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100522474","effects-of-yoga-therapy-in-rehabilitation-compared-to-physiotherapy-in-moderate-axial-spondyloarthritis-axspa-100522474","NCT06083090","Effects of Yoga Therapy in Rehabilitation Compared to Physiotherapy in Moderate Axial Spondyloarthritis (axSPA)","Effects of Yoga Therapy in Rehabilitation Compared to Physiotherapy in Moderate Axial Spondyloarthritis (axSPA): a Randomized Controlled Multicenter Study.","YOKISPA","Inclusion Criteria:\n\n* French-speaking patient aged 18 and over\n* Patient with axial spondyloarthritis (axSPA) according to Assessment of SpondyloArthritis International Society, diagnosed by a rheumatologist\n* \"Moderately active\" to \"active\" form of axSPA (basic BASDAI \\> 3)\n* Stable disease: No recent or foreseeable introduction in the next 6 months of drug treatments for axSPA (excluding analgesics)\n* Absence of disabling stress urinary incontinence\n* Geographical or organizational possibility of undergoing the study\n* Patient informed and having signed the informed consent form for participation in the research\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Recent childbirth (within the last six months)\n* Patient already practicing yoga or having practiced it in the last six months\n* Abdominal or spinal surgery in the last six months\n* Motor neurological deficit\n* Sphincter deficit\n* Any other somatic pathology preventing the practice of physiotherapy or yogatherapy according to the opinion of the evaluating clinician\n* Depressive syndrome requiring specific treatment\n* Non-affiliation to a social security scheme (beneficiary or beneficiary) or to another social protection scheme\n* Patient deprived of liberty by judicial or administrative decision or under legal protection (guardianship, safeguard of justice)\n* Currently participating in or in a period of exclusion from: another interventional research involving human participants, a clinical trial on a medical product for human, a clinical investigation on a medical device. Participation in non-interventional research is authorized.",{"count":143,"type":21},72,[24],"A few studies have evaluated the effectiveness of yoga therapy in patients with axial spondyloarthritis (axSPA). On the other hand, studies conducted in other chronic rheumatisms such as low back pain, rheumatoid arthritis or other conditions such as cancer have shown that yogatherapy can have a effective action on the physical and psychological level.\n\nYogatherapy is a non-drug \"body-mind\" approach that would be likely to improve the physical symptoms (pain, stiffness, in particular spinal and pelvic), internal organs (colitis) and psychological symptoms as well as the perception of fatigue of people with axSPA. A 2021 study showed the feasibility and acceptability of regular yogatherapy practice in patients with axSPA.\n\nIt is therefore necessary to conduct randomized controlled studies to assess the effectiveness of this management strategy.",[147],"Axial Spondyloarthritis (axSPA)",[149,150,151,152,153],"Yogatherapy","Ankylosing Spondyloarthritis","Physiotherapy","Yoga","Rheumatism","2025-09-30",{"date":156,"type":40},"2025-10-01",{"date":158,"type":40},"2024-08-27",{"date":160,"type":21},"2028-08-27",{"name":162,"class":47},"Assistance Publique - Hôpitaux de Paris",5,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":172,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":5},"100605262","phase-4-redo-jak-dose-reduction-of-janus-kinase-inhibitors-in-patients-with-inflammatory-rheumatic-diseases-100605262","NCT07160231","REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases","REDO-JAK: Dose REDuction Of JAnus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases","REDO-JAK","Inclusion Criteria:\n\n* Patients ≥ 16 years of age\n* Clinical diagnosis of RA, PsA or axSpA\n* Treated with a JAKi (monotherapy or combination with csDMARDwith a JAKi dose ≥ 50% of the authorised dose)\n* LDA or remission for at least 6 months according to accepted criteria for the specific disease and\u002For the judgement of the treating rheumatologist and patient. (RA: DAS28-CRP \\\u003C 2.9; PsA: PASDAS ≤3.2 and psoriasis mBSA involvement ≤3%; axSpA: ASDAS \\\u003C2.1.)\n\nExclusion Criteria:\n\n* Comorbidity for which continued JAKi treatment is expected to be necessary (e.g. active Crohn's disease, ulcerative colitis)\n* Life expectancy ≤12 months\n* Pregnancy (JAKi are contra-indicated during pregnancy, therefore we do not expect patients using a JAKi while pregnant)\n* Patients who are enrolled in other trials that might mutually interfere\n* Not able to provide informed consent","16 Years",{"count":174,"type":21},200,[59],"The goal of this clinical trial is to assess the effectiveness of a disease activity guided dose reduction strategy of Janus kinase inhibitor (JAKi) compared to disease activity guided JAKi continuation in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) who are in a state of low disease activity or remission while on JAKi. The main question it aims to answer is:\n\nIs a disease activity guided dose reduction strategy for JAKi not inferior in terms of efficacy compared to disease activity guided JAKi continuation in patients with RA\u002FPsA\u002FaxSpA that are currently in a low disease activity\u002Fremission state?\n\nResearchers will compare a disease activity guided dose reduction strategy for JAKi to disease activity guided JAKi continuation in patients with RA\u002FPsA\u002FaxSpA that are currently in a low disease activity\u002Fremission state to see if a disease activity guided dose reduction strategy for JAKi is not inferior in terms of efficacy compared to disease activity guided JAKi continuation.\n\nParticipants will:\n\n* Follow a JAKi dose reduction strategy or will continue using JAKi in the same dose\n* Study (telemonitoring) visits are planned every 3 months\n* At every visit, patients are asked to complete patient-reported outcomes that assess daily functioning, health-related quality of life, pain, fatigue, productivity loss, medical consumption and medication adherence.",[178,179,27],"Rheumatoid Arthritis (RA)","Psoriatic Arthritis (PsA)",[181,182,183],"disease activity guided dose reduction","Janus kinase inhibitors (JAKi)","disease activity guided JAKi continuation","2025-09-16",{"date":186,"type":40},"2025-09-17",{"date":188,"type":40},"2025-09-15",{"date":190,"type":21},"2028-05-01",{"name":192,"class":47},"Sint Maartenskliniek",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":203,"studyType":115,"phases":4,"briefSummary":204,"conditions":205,"keywords":211,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":48},"100578173","a-longitudinal-observational-study-to-evaluate-the-efficacy-of-movement-and-implement-concrete-movement-recommendations-with-the-help-of-mobility-tracking-with-smartwatches-in-subjects-with-axial-spondyloarthritis-100578173","NCT06807853","A LONGITUDINAL OBSERVATIONAL STUDY to EVALUATE the EFFICACY of MOVEMENT and IMPLEMENT CONCRETE MOVEMENT RECOMMENDATIONS with the HELP of MOBILITY TRACKING with SMARTWATCHES in SUBJECTS with AXIAL SPONDYLOARTHRITIS","SYMPTOM-ACCESSMENT in SUBJECTS with AXIAL SPONDYLOARTHRITIS with PATIENT-REPORTED OUTCOMES and MOBILITY TRACKING with SMARTWATCHES VIA SPECIALLY PROGRAMMED STUDY-APP to EVALUATE the EFFICACY of MOVEMENT and IMPLEMENT CONCRETE MOVEMENT RECOMMENDATIONS","SPARTAKUS","Inclusion Criteria:\n\n* Patients with Axial Spondyloarthritis\n* Patients do must have an own iPhone due to software reasons\n* do must be willing and able to wear a Smartwatch\n* do must be able to regularly fill out the PROs at home\n\nExclusion Criteria:\n\n* no iphone\n* no physical or mental Ability to wear a Smartwatch\n* no physical or mental Ability to regularly fill out the PROs at home",{"count":202,"type":21},50,"6 Months","Axial spondyloarthritis (axSpa) is a chronic inflammatoric autoimmune disease of the back with a prevalence around 1,4% (1) . In patients decreased function and decreased quality of life as well as chronic pain are strong burdens . Despite modern treatments like biological agents just 25% of the patients are at remission (2) . Besides the pharmacological treatment physical activity is known to be very important to gain disease control. A low physical activity is related to a higher disease activity and a high physical activity to better disease control. Until now there is no structured capture of the daily movements of patients with axial spondylarthritis in clinical practice. Our goal is to analyse the relationship between movement and disease activity and to implement concrete recommendations for movement in patients with axSpa.\n\nThe primary objective of the study is to investigate which type, frequency and intensity of movement are helpful in gaining and remaining disease control in patients with axSpa.\n\nMethods This monocentric longitudinal study recordes movement, sport and physical parameters like heart frequency and heart rate variability through an observational period of 6 month via smartwatch. Meanwhile we record disease activity, pain and functional outcomes with regular surveys every two weeks. Patients in every phase of disease are eligible for inclusion, but they do must have an own iPhone due to software reasons. Data is collected in a specially programmed study-app. Fifty participants will be included in this study. Until now we have 24 patients included since april 2024. Patients come to clinic every 3 month as this is our standard in outclinic patients. We than do anamnesis and a physical examination. After the study period of 6 month we transmit the mobility and disease-related data of the surveys of the patients mobile device to our system.\n\nThe primary endpoint is to find exact recommendations for concrete movement in patients with axSpa.\n\nSo this is the first study that wants to give concrete recommendations for movement in patients with axSpa with the help of mobility tracking with smartwatches. This could help to prevent flares and also to recover quicker from a flare.\n\n1. López-Medina und Moltó, \"Update on the epidemiology, risk factors, and disease outcomes of axial spondyloarthritis\".\n2. Pina Vegas u. a., \"Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort\".",[30,27,206,207,208,209,210],"Axial Spondylarthritis (r-axSpA)","Axial Spondyloarthopathy","Axial Spondyloarthritis and Ankylosing Spondylitis","Axial Spondyloarthritis, Non-Radiographic","Axial and Peripheral Spondyloarthritis",[212,213,35,214,215,216,217],"Mobility Tracking","Patient-Reported Outcomes (PROs)","Smartwatch","Study-App","Mobile Device","Movement Recommedations","2025-02-13",{"date":220,"type":40},"2025-02-18",{"date":222,"type":40},"2024-04-01",{"date":224,"type":21},"2025-11",{"name":226,"class":47},"University of Bonn"]